Research on Ipamorelin, CJC-1295, and GHRH analogs
Growth hormone secretagogues (GHS) are compounds that stimulate the pituitary gland to increase growth hormone (GH) production. These include growth hormone releasing hormone (GHRH) analogs and growth hormone releasing peptides (GHRPs), each acting through distinct receptor pathways.
Ipamorelin
Selective GHRP, 5 amino acids, minimal side effects
CJC-1295
Modified GHRH (1-29), extended half-life with DAC
GHRP-6
Hexapeptide GH secretagogue, increases ghrelin
Sermorelin
GHRH analog (1-29), bioidentical sequence
Growth hormone secretagogues work through two primary receptor systems:
GHRH Receptor Pathway
CJC-1295 and Sermorelin bind to GHRH receptors on pituitary somatotrophs, stimulating GH synthesis and release through cAMP-mediated signaling.
Ghrelin/GHS Receptor Pathway
Ipamorelin and GHRP-6 activate ghrelin receptors (GHS-R1a), working synergistically with GHRH to amplify GH pulsatile release.
Combination protocols: Research often combines GHRH analogs with GHRPs to maximize GH release through dual receptor activation.
Lyophilized Powder
Store at -20°C for long-term stability. Can be stored at 2-8°C for up to 3 months.
Reconstituted Solution
Refrigerate at 2-8°C. Ipamorelin: stable 3-4 weeks. CJC-1295 w/DAC: stable 4+ weeks.
Reconstitution
Use bacteriostatic water. Let peptide equilibrate to room temperature before reconstituting.
Growth hormone secretagogues are sold strictly for laboratory research purposes. They are not approved for human or veterinary use. This information is provided for educational purposes only and does not constitute medical advice.